Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialIvan Fan-Ngai Hung, Kwok-Yung Yuen, Yuk-Yung Ng et al.|The Lancet|2020Cited by 1.6k
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell ResponsesRunhong Zhou, Zhiwei Chen, Kelvin Kai‐Wang To et al.|Immunity|2020Cited by 569
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell ResponsesRunhong Zhou, Zhiwei Chen, Kelvin Kai‐Wang To et al.|SSRN Electronic Journal|2020Cited by 25